Anti-HMGB1 therapy would interrupt this cascade by neutralizing the extracellular HMGB1, thereby preventing inflammatory responses and strong vasospasm in the BA, and ultimately reducing the ischemia-induced brain damage and improving the neurological symptoms. This evidence concerns the gene HMGB1 and ischemia.